2023-506854-19-00招募中1 期
IMA401-101 – Treatment of patients with solid tumors with IMA401 TCER®, a bispecific T-cell receptor (Phase I trial); alone or in combination with checkpoint inhibitor
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 95
- 试验地点
- 23
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Development
Scientific
Immatics Biotechnologies GmbH
研究点 (23)
Loading locations...
相似试验
招募中
1 期
A Phase 1 Study of HDM2017 in Advanced Solid TumorsNCT07274085Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.96
招募中
1 期
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors2022-500508-23-00Merck Healthcare KGaA116
进行中（未招募）
1/2 期
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anticancer agents in patients with HER2-positive Metastatic Breast Cancer inclusive of patients with active and stable brain metastases2023-505309-18-00AstraZeneca AB46
招募中
1 期
VSV-02 Compassionate Use in Advanced Solid TumorsBreast CancerLung CancerMelanomaNCT07260591The First Affiliated Hospital of Xinxiang Medical College6
招募中
1 期
BTM-3566 in Advanced Solid TumorsNCT07266285Bantam Pharmaceuticals30